A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
NCT ID: NCT00716859
Last Updated: 2021-02-03
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
139 participants
INTERVENTIONAL
2008-07-31
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-Term Non-Interventional Latanoprost Study
NCT01265719
A Study of Glaucoma or Ocular Hypertension in Patients Within the United States
NCT00800267
A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients
NCT00856622
A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT00311389
A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.
NCT00638742
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Timolol
Timolol
Timolol 0.5% dosed twice-daily
latanoprost
latanoprost
Latanoprost 0.005% ophthalmic solution dosed once-daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Timolol
Timolol 0.5% dosed twice-daily
latanoprost
Latanoprost 0.005% ophthalmic solution dosed once-daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of glaucoma
* IOP of 22 mmHg or above in at least 1 eye
Exclusion Criteria
* Have had prior cyclodestructive procedures
* Have a history of ocular trauma or surgery in either eye within 3 months of the baseline visit
36 Weeks
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Pembroke Pines, Florida, United States
Pfizer Investigational Site
Atlanta, Georgia, United States
Pfizer Investigational Site
Indianapolis, Indiana, United States
Pfizer Investigational Site
Minneapolis, Minnesota, United States
Pfizer Investigational Site
Henderson, Nevada, United States
Pfizer Investigational Site
Henderson, Nevada, United States
Pfizer Investigational Site
Las Vegas, Nevada, United States
Pfizer Investigational Site
Leuven, , Belgium
Pfizer Investigational Site
Medellín, Antioquia, Colombia
Pfizer Investigational Site
Bogota, Cundinamarca, Colombia
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Amiens, Cedex 1, France
Pfizer Investigational Site
Lille, , France
Pfizer Investigational Site
Lyon, , France
Pfizer Investigational Site
Regenstauf, , Germany
Pfizer Investigational Site
Schorndorf, , Germany
Pfizer Investigational Site
Hyderabad, Andhra Pradesh, India
Pfizer Investigational Site
Ahmedabad, Gujarat, India
Pfizer Investigational Site
Coimbatore, Tamil Nadu, India
Pfizer Investigational Site
Catania, , Italy
Pfizer Investigational Site
Milan, , Italy
Pfizer Investigational Site
Makati City, , Philippines
Pfizer Investigational Site
Mandaluyong, , Philippines
Pfizer Investigational Site
Bialystok, , Poland
Pfizer Investigational Site
Gdansk, , Poland
Pfizer Investigational Site
Wroclaw, , Poland
Pfizer Investigational Site
Coimbra, , Portugal
Pfizer Investigational Site
Lisbon, , Portugal
Pfizer Investigational Site
Lisbon, , Portugal
Pfizer Investigational Site
Lisbon, , Portugal
Pfizer Investigational Site
Porto, , Portugal
Pfizer Investigational Site
Cluj-Napoca, Cluj, Romania
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Saint Petersburg, , Russia
Pfizer Investigational Site
Belgrade, , Serbia
Pfizer Investigational Site
Bratislava, , Slovakia
Pfizer Investigational Site
Ljubljana, , Slovenia
Pfizer Investigational Site
Myfair West, , South Africa
Pfizer Investigational Site
Esplugues de Llobregat, Barcelona, Spain
Pfizer Investigational Site
Madrid, , Spain
Pfizer Investigational Site
Seville, , Spain
Pfizer Investigational Site
Kharkiv, , Ukraine
Pfizer Investigational Site
Kyiv, , Ukraine
Pfizer Investigational Site
Kyiv, , Ukraine
Pfizer Investigational Site
Kyiv, , Ukraine
Pfizer Investigational Site
Odesa, , Ukraine
Pfizer Investigational Site
Birmingham, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A6111137
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.